This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo

Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., et al. (2001). Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. CANCER RESEARCH, 61(20), 7501-7506.

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

Carrabba, G;GIUSSANI, CARLO GIORGIO;
2001

Abstract

This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo
Articolo in rivista - Articolo scientifico
Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cell Division; Dose-Response Relationship, Drug; Etoposide; Glioblastoma; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Peptide Fragments; Recombinant Proteins; Xenograft Model Antitumor Assays
English
2001
61
20
7501
7506
reserved
Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., et al. (2001). Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. CANCER RESEARCH, 61(20), 7501-7506.
File in questo prodotto:
File Dimensione Formato  
Low dose chemotherapy.pdf

Solo gestori archivio

Dimensione 235.24 kB
Formato Adobe PDF
235.24 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/148283
Citazioni
  • Scopus 174
  • ???jsp.display-item.citation.isi??? 161
Social impact